GT601
/ Grit Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 03, 2025
Trial in Progress: First in Human Study of GT601, a Next-Generation Neoantigen Cancer Vaccine for Hepatocellular Carcinoma
(SITC 2025)
- "Any additional data that will be available on a poster that is beyond what was submitted in the abstract is embargoed until Nov. 7, 2025 at 9 a.m. ET."
First-in-human • P1 data • Tumor-specific neoantigens • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1